Deals
Ultragenyx Agrees To Sell FDA Priority Review Voucher For $210 Million Cash, 8-K Says
The drugmaker owes the NIH 20% of gross proceeds, and the sale still needs antitrust waiting-period clearance before it closes.
Editor @TheBullished. Ex-Forbes reporter/editor, UNC Chapel Hill, Columbia MBA. Bringing smart coverage and analysis to every corner of the stock market.
Deals
The drugmaker owes the NIH 20% of gross proceeds, and the sale still needs antitrust waiting-period clearance before it closes.
SEC Filings
Tom Lee's Wednesday presentation, furnished in an 8-K, says Bitmine is about 100,000 ETH short of its 5% supply goal.
SEC Filings
The board treated Bishop's exit as a termination without cause; Latino's base salary is $460,000 plus a $120,000 sign-on bonus.
SEC Filings
The board grew from nine to 10 seats, and the new independent director joins two committees, according to an 8-K.
SEC Filings
An 8-K says the sale funds a late-stage SPY072 program in hidradenitis suppurativa, with closing expected on or about Wednesday.
SEC Filings
The annual proxy keeps one person as chair and CEO, with a lead independent director and seven independent nominees out of eight.
Deals
The Swiss sports-data company plans to keep several technology assets already built into its core products, and expects to close in the fourth quarter.
SEC Filings
The annual proxy filing shows an $8.67 adjusted share profit alongside a $92.96 per-share loss under standard accounting.
SEC Filings
A new AI retention program added stock grants and one cash award on top of regular executive pay, the annual proxy filing shows.
SEC Filings
The cannabis company says an annual and special meeting was adjourned for lack of quorum and a second delay would cost more.
SEC Filings
The annual proxy shows $6,928,561 in fiscal 2026 pay for former CEO Julie Masino; David Deno has been CEO since August 2026.
SEC Filings
The annual proxy filing also puts CEO Philip Gallagher's total pay at $11,980,898 and asks holders to re-elect all ten directors.